Reviewing RYTHM (NASDAQ:RYM) and Dare Bioscience (NASDAQ:DARE)

RYTHM (NASDAQ:RYM) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Analyst Recommendations

This is a summary of recent ratings and target prices for RYTHM and Dare Bioscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1	0	0	0	1.00
Dare Bioscience	1	0	2	0	2.33

Dare Bioscience has a consensus target price of $6.50, suggesting a potential upside of 740.44%. Given Dare Bioscience’s stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than RYTHM.

Profitability

This table compares RYTHM and Dare Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Dare Bioscience	-803.80%	-748.30%	-38.75%

Volatility & Risk

RYTHM has a beta of 9.46, indicating that its stock price is 846% more volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.

Earnings and Valuation

This table compares RYTHM and Dare Bioscience”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28 million	2.66	-$33.26 million	($10.53)	-2.00
Dare Bioscience	$1.03 million	14.77	-$13.40 million	($0.70)	-1.10

Dare Bioscience has lower revenue, but higher earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

6.0% of RYTHM shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 3.5% of RYTHM shares are held by insiders. Comparatively, 4.1% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Dare Bioscience beats RYTHM on 9 of the 14 factors compared between the two stocks.

About RYTHM

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.

About Dare Bioscience

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.